Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.25
Bid: 1.10
Ask: 1.40
Change: -0.05 (-3.85%)
Spread: 0.30 (27.273%)
Open: 1.30
High: 1.30
Low: 1.25
Prev. Close: 1.30
PYC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Further Agreement with Eli Li

14 Jul 2008 07:30

RNS Number : 7733Y
Physiomics PLC
14 July 2008
 



Physiomics plc

The Magdalen Centre

The Oxford Science ParkRobert Robinson AvenueOxford

OX4 4GAUK

Tel 01865 784980

Fax 08701 671931

14 July 2008

Physiomics plc ("Physiomics" or "the Company")

Physiomics Technology in continued and expanded support of Lilly's Oncology Programs 

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a further agreement with Eli Lilly and Company ('Lilly') (NYSE: LLY), the global pharmaceutical company, to perform two new projects for in silico simulations in the field of oncology. Financial details of this agreement have not been disclosed. This follows the successful completion earlier this year of a specific project studying cancer cellular processes for drugs targeting the cell cycle (the natural process of controlling cell proliferation).

The overall aim of the first new project is to provide a rationale for the identification of patient subpopulations that could benefit from an undisclosed target inhibitor (drug candidate). Physiomics' role is to provide this rationale, based on identifying and illustrating the mechanisms underlying the response of cells with different genetic backgrounds to this class of inhibitors given alone and in combination with other drugs

For the second project, a customised model will be produced which integrates various biomarkers currently being investigated by Lilly as functional readouts for proprietary undisclosed target (distinct from the above-mentioned target) inhibitors. The model will provide a rational mechanistic understanding of the involvement of these biomarkers in the functional response to the inhibitors. In so doing, the model will be used to select optimal dosing regimes for the drugs either alone or in combination with other drugs.

Dr Christophe Chassagnole, COO of Physiomics, said:

'Clearly we are very pleased to be able to continue and expand our collaboration with Lilly following the satisfactory completion of a preliminary study designed to evaluate the technology and the team.  The needs of Lilly's discovery and development teams are very well matched to Physiomics's key expertise and capabilities in the challenging area of oncology. This is a vote of confidence in our team and our ability to apply systems biology approach to the pharma R&D processe.'

For further information:

Physiomics plc +44 (0)1865 784980

Dr Christophe Chassagnole, COO 

E-mail: cchassagnole@physiomics-plc.com

Grant Thornton UK LLP +44 (0)20 7383 5100

Colin Aaronson, Philip Secrett 

 

About Physiomics plc
Physiomics plc (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. As 80-90 per cent of all clinical drug candidates fail to reach the market, estimates1 show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million.
Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating most important molecular events taking place during the human cell cycle and apoptosis processes. Physiomics developed SystemCell® technology, a multi-cellular environment software, which enables the simulation of population of "virtual cells".
Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com
 
SystemCell® is a registered trademark of Physiomics plc
1Tufts Centre Impact Report 2002

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRBGGDRSGBGGIG
Date   Source Headline
3rd May 20247:00 amRNSTrading Update
21st Mar 20247:00 amRNSIMC Presentation on Company Website
18th Mar 20247:00 amRNSContract Award
7th Mar 20247:00 amRNSInterim Results
1st Mar 20243:00 pmRNSNotice of Results and Investor Presentation
19th Feb 20247:00 amRNSContract Award
6th Feb 20247:00 amRNSOptions Award
5th Feb 20247:00 amRNSContract Award
2nd Feb 20247:00 amRNSIMC Presentation on Company Website
23rd Jan 20247:00 amRNSIMC Presentation on Board Changes
22nd Jan 20247:00 amRNSBoard Changes
21st Nov 20233:30 pmRNSResult of AGM
10th Nov 20233:14 pmRNSBusiness Update Presentation
10th Nov 20237:00 amRNSInnovate UK grant award
18th Oct 20237:00 amRNSNotice of AGM
4th Oct 20237:00 amRNSChange of Registered Office
3rd Oct 20237:00 amRNSSenior Management Announcement
28th Sep 20237:00 amRNSAnnual Financial Report
4th Sep 20237:00 amRNSSenior Management Update
31st Aug 20231:00 pmRNSContract Award
31st Aug 20237:00 amRNSContract Award
8th Aug 20237:45 amRNSContract Award
4th Aug 20237:00 amRNSContract Award
25th Jul 20237:00 amRNSDirector Dealing
18th Jul 20237:00 amRNSDirector Dealing
29th Jun 20237:00 amRNSCompletion of Placing, Subscription & Retail Offer
27th Jun 20237:01 amRNSWRAP Retail Offer for up to £150,000
27th Jun 20237:00 amRNSCompletion of Equity Fundraise
31st May 20237:00 amRNSCollaboration with The University of Sheffield
23rd May 20237:00 amRNSTrading Update
9th May 20237:00 amRNSPublication of article in Frontiers in Oncology
26th Apr 20237:00 amRNSCollaborative Services Agreement
14th Apr 20237:00 amRNSPhysiomics to present at AACR Annual Meeting
4th Apr 20237:00 amRNSTrading and Company Update
28th Mar 20237:00 amRNSAnnouncement of Collaboration
10th Mar 20237:00 amRNSContract announcement
7th Mar 20237:00 amRNSInterim Results
13th Jan 20237:00 amRNSChange in role of board Director
11th Jan 20237:00 amRNSContract announcement
9th Jan 20237:00 amRNSCompletion of PARTNER study
22nd Nov 20224:00 pmRNSResult of AGM
10th Nov 20228:50 amRNSContract award
9th Nov 20227:00 amRNSPYC to present and exhibit at SITC Annual Meeting
27th Oct 20227:00 amRNSAnnual Report and AGM Notice
14th Oct 20227:00 amRNSConference Attendance
12th Oct 20227:00 amRNSContract Award
4th Oct 20227:00 amRNSContract Award
29th Sep 20227:00 amRNSInterim Results
9th Sep 20227:00 amRNSNotice of Results
1st Sep 20227:00 amRNSAppointment of Independent Non-Executive Director

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.